Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416598 | 0.94 | TSPO (0.42) | TSPOHCRTR1HCRTR2TEAD3TACR1 | |
| SCHEMBL420135 | 0.90 | TSPO (0.41) | TSPO | |
| SCHEMBL460215 | 0.89 | TSPO (0.56) | TSPO | |
| SCHEMBL28254010 | 0.85 | HTR6 (0.38) | TSPOHCRTR1HCRTR2TEAD3 | |
| SCHEMBL28412710 | 0.83 | HTR6 (0.41) | TSPO | |
| SCHEMBL6693579 | 0.82 | FABP4 (0.44) | TSPOHCRTR1HCRTR2 | |
| SCHEMBL12748229 | 0.82 | TSPO (0.44) | TSPO | |
| SCHEMBL12748236 | 0.82 | TSPO (0.44) | TSPO | |
| SCHEMBL12748241 | 0.82 | TSPO (0.44) | TSPO | |
| SCHEMBL22210606 | 0.81 | LTA4H (0.33) | TSPOHCRTR1HCRTR2TEAD3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| EP-3022178-B1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE HEALTHCARE LTD (GB) | 2018-12-26 | — | — | EP | disclosed |
| CN-105452221-B | Enantiomer separation and purification of 2,3,4, 9-tetrahydro-1H-carbazole-4-carboxamide derivatives | 通用电气健康护理有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2552891-B1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| US-9815785-B2 | Enantiomeric separation and purification of 2,3,4,9-tetrahydro-1H-carbazole-4-carboxylic acid amide derivatives | GE HEALTHCARE LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160168091-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| EP-3022178-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE Healthcare Limited (GB) | 2016-05-25 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| WO-2014083113-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014083113-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSPO 50/4885HCRTR1 465/4885HCRTR2 201/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | TSPO 13/4885HCRTR1 578/4885HCRTR2 452/4885 |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | TSPO 9/4885HCRTR1 442/4885HCRTR2 252/4885 |
| US-20160168091-A1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | IDO2, IDO1, TPH2 | TSPO 3560/4885HCRTR1 470/4885HCRTR2 146/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | TSPO 72/4885HCRTR1 29/4885HCRTR2 16/4885 |
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | IDO1, IDO2, TPH1 | TSPO 3643/4885HCRTR1 421/4885HCRTR2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.